A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors
NCT ID: NCT00811993
Last Updated: 2016-11-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE1
104 participants
INTERVENTIONAL
2009-02-28
2012-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
RG1507
Starting dose of \>=3mg/kg iv escalating to a maximum dose of \<=16mg/kg iv, depending on dosing schedule in each combination treatment arm
erlotinib [Tarceva]
as prescribed
gemcitabine
as prescribed
10
RG1507
Starting dose of \>=3mg/kg iv escalating to a maximum dose of \<=16mg/kg iv, depending on dosing schedule in each combination treatment arm
temozolomide
as prescribed
11
RG1507
Starting dose of \>=3mg/kg iv escalating to a maximum dose of \<=16mg/kg iv, depending on dosing schedule in each combination treatment arm
bevacizumab [Avastin]
as prescribed
docetaxel
as prescribed
12
RG1507
Starting dose of \>=3mg/kg iv escalating to a maximum dose of \<=16mg/kg iv, depending on dosing schedule in each combination treatment arm
pemetrexel
as prescribed
13
RO1507
27mg/kg iv, monotherapy
2
RG1507
Starting dose of \>=3mg/kg iv escalating to a maximum dose of \<=16mg/kg iv, depending on dosing schedule in each combination treatment arm
bevacizumab [Avastin]
as prescribed
paclitaxel
as prescribed
3
RG1507
Starting dose of \>=3mg/kg iv escalating to a maximum dose of \<=16mg/kg iv, depending on dosing schedule in each combination treatment arm
carboplatin
as prescribed
etoposide
as prescribed
4
RG1507
Starting dose of \>=3mg/kg iv escalating to a maximum dose of \<=16mg/kg iv, depending on dosing schedule in each combination treatment arm
bevacizumab [Avastin]
as prescribed
mFOLFOX6
as prescribed
5
RG1507
Starting dose of \>=3mg/kg iv escalating to a maximum dose of \<=16mg/kg iv, depending on dosing schedule in each combination treatment arm
capecitabine [Xeloda]
as prescribed
trastuzumab [Herceptin]
as prescribed
6
RG1507
Starting dose of \>=3mg/kg iv escalating to a maximum dose of \<=16mg/kg iv, depending on dosing schedule in each combination treatment arm
sorafenib
as prescribed
7
RG1507
Starting dose of \>=3mg/kg iv escalating to a maximum dose of \<=16mg/kg iv, depending on dosing schedule in each combination treatment arm
bevacizumab [Avastin]
as prescribed
erlotinib [Tarceva]
as prescribed
8
RG1507
Starting dose of \>=3mg/kg iv escalating to a maximum dose of \<=16mg/kg iv, depending on dosing schedule in each combination treatment arm
cetuximab
as prescribed
irinotecan
as prescribed
9
RG1507
Starting dose of \>=3mg/kg iv escalating to a maximum dose of \<=16mg/kg iv, depending on dosing schedule in each combination treatment arm
bevacizumab [Avastin]
as prescribed
carboplatin
as prescribed
paclitaxel
as prescribed
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
RG1507
Starting dose of \>=3mg/kg iv escalating to a maximum dose of \<=16mg/kg iv, depending on dosing schedule in each combination treatment arm
RO1507
27mg/kg iv, monotherapy
bevacizumab [Avastin]
as prescribed
capecitabine [Xeloda]
as prescribed
carboplatin
as prescribed
cetuximab
as prescribed
docetaxel
as prescribed
erlotinib [Tarceva]
as prescribed
etoposide
as prescribed
gemcitabine
as prescribed
irinotecan
as prescribed
mFOLFOX6
as prescribed
paclitaxel
as prescribed
pemetrexel
as prescribed
sorafenib
as prescribed
temozolomide
as prescribed
trastuzumab [Herceptin]
as prescribed
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* malignant neoplasms;
* failed prior standard curative therapy;
* ECOG performance Status of 0 or 1;
* adequate bone marrow, hepatic and renal function;
* life expectancy greater than 8 weeks.
Exclusion Criteria
* prior irradiation within 4 weeks prior to start of therapy;
* prior treatment with agents targeting IGF-IR inhibition, or other investigational agents;
* major surgery or significant traumatic injury within 2 weeks prior to study start;
* patients receiving concurrent antibody or immunotherapy;
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tucson, Arizona, United States
San Francisco, California, United States
Santa Monica, California, United States
Washington D.C., District of Columbia, United States
Chicago, Illinois, United States
Rochester, Minnesota, United States
Chapel Hill, North Carolina, United States
Houston, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NO22068
Identifier Type: -
Identifier Source: org_study_id